A Multicenter, Randomized, and Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of Intramuscular and Inhaled COVID-19 Vaccine in Children Aged 6-12 Years and Adolescents Aged 13-17 Years Who Have Been Immunized With Two Doses of CoronaVac

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics; Registrational
Sponsors Tianjin CanSino Biotechnology

Most Recent Events

14 Jun 2023 Status changed from recruiting to discontinued.
02 Sep 2022 Planned number of patients changed from 2000 to 1000.
02 Sep 2022 Planned End Date changed from 20 Aug 2023 to 25 Aug 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight